| 7.56 0.14 (1.89%) | 06-17 09:38 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.37  |
1-year : | 11.75 |
| Resists | First : | 8.87 |
Second : | 10.06 |
| Pivot price | 7.8 |
|||
| Supports | First : | 6.96 | Second : | 5.79 |
| MAs | MA(5) : | 7.31  |
MA(20) : | 8.08 |
| MA(100) : | 10.92 |
MA(250) : | 10.02 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 23.4 |
D(3) : | 17.3 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 14.51 | Low : | 6.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARVN ] has closed above bottom band by 35.6%. Bollinger Bands are 13.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.55 - 7.6 | 7.6 - 7.65 |
| Low: | 7.18 - 7.23 | 7.23 - 7.27 |
| Close: | 7.35 - 7.43 | 7.43 - 7.49 |
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Wed, 17 Jun 2026
Arvinas (NASDAQ: ARVN) insider sells 2,642 shares; May sale of 9,657 noted - Stock Titan
Wed, 17 Jun 2026
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal - Seeking Alpha
Tue, 16 Jun 2026
Arvinas, Pfizer receive $70M upfront as Rigel deal for VEPPANU clears HSR - TradingView
Tue, 16 Jun 2026
Arvinas (NASDAQ: ARVN) secures $70M VEPPANU payment and major milestones - Stock Titan
Mon, 08 Jun 2026
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Fri, 05 Jun 2026
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 83.2 (%) |
| Shares Short | 4,710 (K) |
| Shares Short P.Month | 4,420 (K) |
| EPS | -3.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6 |
| Profit Margin | -247.6 % |
| Operating Margin | -405.2 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -42.3 % |
| Qtrly Rev. Growth | -91.7 % |
| Gross Profit (p.s.) | 1.86 |
| Sales Per Share | 1.38 |
| EBITDA (p.s.) | -3.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -254 (M) |
| Levered Free Cash Flow | -200 (M) |
| PE Ratio | -2.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 5.35 |
| Price to Cash Flow | -1.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|